STOCK TITAN
  1. Home
  2. News
  3. ALPMY

Astellas Pharma Inc. - ALPMY STOCK NEWS

IMPACT
SENTIMENT
ALPMY : OTC
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
clinical trial
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize
IMPACT
SENTIMENT
ALPMY : OTC
Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society
IMPACT
SENTIMENT
ALPMY : OTC
Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland
IMPACT
SENTIMENT
ALPMY : OTC PFE : NYSE
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
IMPACT
SENTIMENT
ALPMY : OTC PFE : NYSE
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
IMPACT
SENTIMENT
ALPMY : OTC
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy
IMPACT
SENTIMENT
ALPMY : OTC
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
IMPACT
SENTIMENT
PSTX : Nasdaq ALPMY : OTC
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
IMPACT
SENTIMENT
ALPMY : OTC
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
fda approval
Stock ALPMY logo
Astellas Pharma Inc.

OTC:ALPMY

ALPMY Rankings

#575 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ALPMY Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Pharmaceuticals: Other, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
Japan
Chuo Ku